In this regard, CXCL10 can be blocked in vivo by Eldelumab, a humanized mAb that has been used in clinical trials for rheumatoid arthritis and inflammatory bowel diseases [46]. The gene discussed is CXCL10; the disease is rheumatoid arthritis.